Recent advances and strategies for nanocarrier-mediated topical therapy and theranostic for posterior eye disease
Loading...
Official URL
Full text at PDC
Publication date
2024
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Citation
Faria MJ, González-Méijome JM, Real Oliveira MECD, Carracedo G, Lúcio M. Recent advances and strategies for nanocarrier-mediated topical therapy and theranostic for posterior eye disease. Adv Drug Deliv Rev. 2024 Apr 26;210:115321. doi: 10.1016/j.addr.2024.115321. Epub ahead of print. PMID: 38679293.
Abstract
Posterior eye disorders, such as age-related macular degeneration, diabetic retinopathy, and glaucoma, have a significant impact on human quality of life and are the primary cause of age-related retinal diseases among adults. There is a pressing need for innovative topical approaches to treat posterior eye disorders, as current methods often rely on invasive procedures with inherent risks. Limited success was attained in the realm of topical ophthalmic delivery through non-invasive means. Additionally, there exists a dearth of literature that delves into the potential of this approach for drug delivery and theranostic purposes, or that offers comprehensive design strategies for nanocarrier developers to surmount the significant physiological ocular barriers. This review offers a thorough and up-to-date state-of-the-art overview of 40 studies on therapeutic loaded nanocarriers and theranostic devices that, to the best of our knowledge, represent all successful works that reached posterior eye segments through a topical non-invasive administration. Most importantly, based on the successful literature studies, this review provides a comprehensive summary of the potential design strategies that can be implemented during nanocarrier development to overcome each ocular barrier.
Description
Received 16 February 2024, Revised 8 April 2024, Accepted 19 April 2024, Available online 26 April 2024, Version of Record 15 May 2024.
This work was supported by the Portuguese Foundation for Science and Technology (FCT, UIDB/04650/2020, Portugal). Maria João Faria acknowledges FCT I.P. for PhD grant (2020.06561.BD).
20234. Acuerdos transformativos CRUE-CSIC